
What Pharmacists Should Know About Transitioning Patients to Buprenorphine
Key Takeaways
- Buprenorphine can trigger precipitated withdrawal if started while full-agonist opioid effects persist, so initiation should be individualized, particularly with fentanyl or other high-potency synthetic opioid exposure.
- Symptom-gated withdrawal-based initiation relies on clear patient-facing criteria and escalation contacts, with methadone transitions requiring verification of last dose, product selection, and supervised handoff.
Pharmacists can help patients start buprenorphine for opioid use disorder by confirming when to take the first dose, whether another opioid continues during initiation, and who will manage symptoms and follow-up.
At the pharmacy counter, a patient picking up buprenorphine may ask what to do with the opioid they already take. The answer depends on how they are starting treatment. The American Society of Regional Anesthesia (ARSA) and Pain Medicine scheduled 2 November 5 problem-based learning discussions on low-dose, rapid, and withdrawal-based initiation at its 25th Annual Pain Medicine Meeting in Tampa, Florida.1
For pharmacists dispensing buprenorphine for opioid use disorder (OUD), the distinction matters from the first dose. Buprenorphine is a partial mu-opioid receptor agonist with high receptor affinity. If it displaces a full agonist while that opioid is still exerting substantial effects, opioid signaling can drop abruptly and cause precipitated withdrawal. The American Society of Addiction Medicine (ASAM) advises individualizing initiation, particularly for patients exposed to fentanyl or other high-potency synthetic opioids.2
Withdrawal-Based Initiation Depends on Symptoms
With standard initiation, the patient stops the full agonist and starts buprenorphine once clear signs of withdrawal develop. The time since the last opioid dose helps inform the decision, alongside the opioid involved and the patient’s symptoms. For an at-home start, pharmacists can ask what signs the prescriber wants the patient to look for and whom the patient should call if they are unsure whether to take the first dose.2,3
Methadone warrants a specific handoff. The prescribing information for buprenorphine/naloxone sublingual film (Suboxone; Indivior) identifies a greater risk of precipitated or prolonged withdrawal in patients dependent on methadone or other long-acting opioids and recommends sublingual buprenorphine monotherapy for the first 2 days of labeled induction in this population. When a patient is transitioning from methadone, confirm the last dose, the intended buprenorphine product, and which health care professional or program will oversee the transition.2,3
Rapid Initiation Still Starts With Withdrawal
One rapid approach described by ASAM is high-dose initiation, in which clinicians escalate buprenorphine quickly after withdrawal begins, most often in an emergency department (ED). A retrospective study of EDs that used a high-dose approach documented precipitated withdrawal in approximately 1.6% of patients given buprenorphine overall and in 4.5% of the subgroup who reported fentanyl use. The fentanyl subgroup was small, and exposure was self-reported. For a prescription written at ED discharge, the pharmacist can confirm what the patient already received and when the first take-home dose is due.2,4
Low-Dose Initiation Requires a Clear Overlap Plan
Low-dose buprenorphine initiation with opioid continuation, sometimes called microdosing, starts with small doses of buprenorphine and increases them over several days while full-agonist opioid exposure continues temporarily. Clinicians can consider this approach when an initial period of abstinence is difficult to tolerate, including for some patients who still need opioids for pain. A patient needs explicit instructions about which opioid is involved and when the overlap ends.2
In a retrospective study of 126 adults who reported daily fentanyl use across 2 outpatient clinics, 60 of 175 low-dose initiation attempts (34%) met the study’s definition of success, which required patients to report completing initiation and pick up a maintenance refill. The study illustrates why a follow-up plan matters even after the starter prescription has been filled.5
What to Clarify Before Dispensing
A day-by-day schedule helps the pharmacist reconcile the prescribed dose with the product strength and quantity on the prescription. If the directions call for a fraction of a film, verify the specific product and clarify the plan with the prescriber. Suboxone film labeling directs patients to administer the film whole. Check stock and coverage early, especially when a starter prescription and a separate maintenance prescription are both needed.2,3,5
At pickup, ask the patient to explain when they will start and what happens with any overlapping opioid. Make sure they know whom to call if withdrawal worsens suddenly. Review alcohol and other sedating medications because they can increase the risk of respiratory depression. Confirm access to rescue naloxone and make sure the patient knows when and where follow-up will occur. For patients who are leaving an ED or hospital, verify that the supply will last until the next visit.2,3
REFERENCES
ASRA Pain Medicine. 25th Annual Pain Medicine Meeting schedule at a glance. November 5–7, 2026. Accessed November 19, 2026.
https://asra.com/docs/default-source/events-education-documents/pm26/pm26-schedule-at-a-glance-for-web.pdf Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp BA, Ramsey KS. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids. J Addict Med. 2023;17(6):632-639. doi:10.1097/ADM.0000000000001202
Suboxone. Prescribing information. Indivior Inc; 2025. FDA prescribing information.
https://www.indivior.com/dam/documents/our-products/country-medicines/us/Suboxone_PI.pdf Snyder H, Chau B, Kalmin MM, et al. High-Dose Buprenorphine Initiation in the Emergency Department Among Patients Using Fentanyl and Other Opioids. JAMA Netw Open. 2023;6(3):e231572. doi:10.1001/jamanetworkopen.2023.1572
Suen LW, Chiang AY, Jones BLH, et al. Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl. JAMA Netw Open. 2025;8(1):e2456253. doi:10.1001/jamanetworkopen.2024.56253
Related to this article







